Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Hatim Allawi"'
Autor:
Karthik V. Giridhar, Fergus J. Couch, Jason P. Sinnwell, Seth W. Slettedahl, William R. Taylor, Douglas W. Mahoney, Patrick H. Foote, Maria C. O’Connell, Mariah J. Robran, Mary E. Devens, Anna M. Gonser, Nicole Larson, Karen A. Doering, Kelli N. Burger, Michael Kaiser, Hatim Allawi, Kathryn Ruddy, Janet Olson, John B. Kisiel
Publikováno v:
Cancer Research. 83:P2-11
Objective: Aberrantly methylated DNA may be used to detect minimal residual disease or early recurrence in breast cancer. As a 1st step, we aimed to develop an MDM panel to delineate between healthy women, stage I-III breast cancer in remission with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b43a809c977dd9875037102fa5588834
https://doi.org/10.1158/1538-7445.sabcs22-p2-11-06
https://doi.org/10.1158/1538-7445.sabcs22-p2-11-06
Autor:
Alanna Chan, Martin You, Oliver Limbo, Billyana Tsevtanova, Gerald Dodson, Brenda Curiel, Karma Farhat, Samantha Scott, Archana Ramesh, Jacquelyn Hennek, Viacheslav Katerov, Michael Kaiser, Hatim Allawi, Brady P. Culver, Michael Reshatoff, Jorge Garces, Gina Costa
Publikováno v:
Cancer Research. 83:6694-6694
Introduction: Advancements in DNA sequence detection technology and assay design have enabled molecular residual disease (MRD) assays to detect cancer earlier and with greater sensitivity. In Tumor-Informed (TI) strategies, mutations from the tumor a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::760d23545f078a7fb6a0b70958d187f4
https://doi.org/10.1158/1538-7445.am2023-6694
https://doi.org/10.1158/1538-7445.am2023-6694
Autor:
Mario Gomez, Wayne Tam, Kui Nie, Amy Chadburn, Daniel M. Knowles, Hatim Allawi, Y. Lynn Wang, Yifang Liu, Taotao Zhang
Publikováno v:
The American Journal of Pathology. 177:1470-1479
PRDM1/Blimp-1, a master regulator for B cell terminal differentiation, is a putative tumor suppressor in diffuse large B cell lymphomas (DLBCL). Inactivating mutations of PRDM1 have been previously identified in a subset of nongerminal center B cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15d016a985780a4de5737a9f32f04b0b
https://doi.org/10.2353/ajpath.2010.091291
https://doi.org/10.2353/ajpath.2010.091291
Autor:
Kui, Nie, Taotao, Zhang, Hatim, Allawi, Mario, Gomez, Yifang, Liu, Amy, Chadburn, Y Lynn, Wang, Daniel M, Knowles, Wayne, Tam
Publikováno v:
The American journal of pathology. 177(3)
PRDM1/Blimp-1, a master regulator for B cell terminal differentiation, is a putative tumor suppressor in diffuse large B cell lymphomas (DLBCL). Inactivating mutations of PRDM1 have been previously identified in a subset of nongerminal center B cell-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1ec76f817d774ec60ece7eae64d9881b
https://pubmed.ncbi.nlm.nih.gov/20651244
https://pubmed.ncbi.nlm.nih.gov/20651244